This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $322,302 to Yale University to support research and training focused on implementing medications for opioid use disorder (OUD) as an HIV prevention strategy in probation settings in Eastern Europe. The key objectives are to: 1) Examine barriers and facilitators to implementing a screening-engagement-treatment (SET) strategy to promote OAT scale-up among probation...
This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,338,750 to The Ohio State University to develop and pilot a brief, digitally-enhanced intervention called IMPROVE for reducing alcohol use among individuals receiving medications for opioid use disorder (MOUD). The project has two phases: (1) adapting the IMPROVE intervention content, delivery, and digital tools based on expert and...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a 5-year study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The research aims to: 1) characterize real-world OUD treatment trajectories in the year following hospital encounters among treatment-naive...
This federal Project Grant award of $683,583 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to estimate the potential impacts of four alternative methadone treatment (MT) policy scenarios in New York State. The project will use an agent-based computer simulation model to analyze how changes to MT access points, such as through OTPs, mobile units, prescribers, and pharmacies, could influence methadone...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...
This $1,192,612 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives are to: 1) conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims and emergency department data; 2) use an evidence-based quality improvement...
INTEGRATING TREATMENT FOR MENTAL DISORDERS IN METHADONE CLINICS IN UKRAINE - PROJECT SUMMARY UKRAINE IS A MIDDLE-INCOME COUNTRY PROFOUNDLY IMPACTED BY OPIOID USE DISORDERS. DESPITE OPIOID AGONIST THERAPIES (OAT) LIKE BUPRENORPHINE AND METHADONE BEING AVAILABLE SINCE 2004, TREATMENT OUTCOMES HAVE BEEN UNDERMINED BY A NUMBER OF PATIENT-, CLINIC- AND STRUCTURAL-LEVEL BARRIERS. CURRENTLY, OAT IS PRESCRIBED IN NARCOLOGY CENTERS, AN ADDICTION SUBSPECIALTY OF PSYCHIATRY. DESPITE SIMILAR TRAINING BY NARCOLOGISTS AND PSYCHIATRISTS, THE SILOED AND FRAGMENTED SEMASHKO SOVIET-STYLE HEALTHCARE SYSTEM LEGACY HAS RESULTED IN OAT PATIENTS NOT RECEIVING TREATMENT FOR CO-OCCURRING PSYCHIATRIC DISORDERS (COD) UNLESS THEY ARE REFERRED OFFSITE TO PSYCHIATRIC CENTERS. DEPRESSION SEVERE ENOUGH TO WARRANT PHARMACOTHERAPY WITH FIRST-LINE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) NOW EXCEEDS 50% OF OAT PATIENTS, YET ONLY 11% HAVE BEEN DIAGNOSED AND 1.2% ARE PRESCRIBED SSRIS. THIS LEAVES CONSIDERABLE ROOM FOR IMPROVEMENT IN MANAGING COD. THIS APPLICATION SEEKS TO USE IMPLEMENTATION SCIENCE AND THE PARIHS FRAMEWORK TO OVERCOME OBSTACLES TO THE COD CONTINUUM OF CARE (SERVICE-LEVEL OUTCOMES) BY INTRODUCING A MODIFIED SCREENING, BRIEF INTERVENTION AND REFERRAL TO TREATMENT (MSBIRT), AN EVIDENCE-BASED PRACTICE (EBP) THAT IMPROVES MENTAL HEALTH OUTCOMES. IN THIS FRAMEWORK, MSBIRT IS THE EBP THAT WE HYPOTHESIZE WILL RESULT IN SSRI PRESCRIPTION TO TREAT DEPRESSION. EFFECTIVELY TREATING DEPRESSION IN OAT CLIENTS WITH COD IS ASSOCIATED WITH A NUMBER OF PATIENT-LEVEL OUTCOMES LIKE REDUCED OAT DROPOUT AND DRUG USE, IMPROVED PSYCHOLOGICAL QUALITY OF LIFE, AND LOWER CRIMINAL ACTIVITIES AND HIV RISK BEHAVIORS. CURRENT STANDARD OF CARE (SOC) IS FOR NARCOLOGISTS TO REFER OAT PATIENTS OFFSITE FOR PSYCHIATRIC ASSESSMENT, DESPITE THEIR ABILITY TO PRESCRIBE SSRIS. SOC CLINICS AND THEIR PATIENTS WILL BE COMPARED OAT CLINICS/PATIENTS INTEGRATING MSBIRT PRACTICES WITH ONGOING COACHING USING PROJECT ECHO. OUR ECHO-COD IS EVIDENCE-BASED FACILITATION PRACTICE THAT WILL PROVIDE SKILLS AND ONGOING SUPPORT FOR NARCOLOGISTS TO PROVIDE ONSITE AND INTEGRATED PSYCHIATRIC TREATMENT FOR DEPRESSION. CLINICS IMPLEMENTING MSBIRT WILL BE FURTHER STRATIFIED USING PAY-FOR-PERFORMANCE (P4P) INCENTIVES, WHICH WE HAVE STUDIED IN UKRAINE TO DETERMINE THEIR MOTIVATION FOR ACHIEVING PRE-SPECIFIED QUALITY INDICATORS (ELEMENTS OF THE COD CONTINUUM OF CARE). INTEGRATING TREATMENTS FOR MANAGING COD THROUGH HEALTHCARE INTEGRATION AND P4P ECONOMIC INCENTIVES ARE PRIORITIZED AND ALIGNED WITH UKRAINE'S NEW HEALTHCARE REFORM PLAN AND THIS PROPOSAL IS SUPPORTIVE BY THE MINISTRY OF HEALTH. THE SPECIFIC AIMS ARE: 1) TO COMPARE BOTH SERVICE-LEVEL (MSBIRT ELEMENTS) AND PATIENT-LEVEL (SSRI INITIATION, OAT DROP-OUT AND PSYCHIATRIC QUALITY OF LIFE) OUTCOMES IN 1,350 PATIENTS WITH OPIOID USE DISORDERS RECEIVING OAT FROM 4 REGIONS (CLUSTERS) AND 12 CLINICAL SETTINGS USING A RANDOMIZED, CLUSTER-CONTROLLED DESIGN OVER 24 MONTHS. BEFORE SITE RANDOMIZATION, ALL OAT CLIENTS AT EACH PARTICIPATING SITE WILL HAVE BASELINE ASSESSMENTS FOLLOWED BY SITE RANDOMIZATION TO RECEIVE STANDARD OF CARE (N=450) VERSUS INTEGRATED CARE USING ECHO-COD FACILITATION WITH (N=450) OR WITHOUT (N=450) P4P INCENTIVES; 2) USING A MULTI-LEVEL IMPLEMENTATION SCIENCE FRAMEWORK, TO EXAMINE THE CONTRIBUTION OF PATIENT, CLINICIAN AND ORGANIZATIONAL FACTORS THAT CONTRIBUTE TO THE SERVICE-LEVEL AND PATIENT-LEVEL OUTCOMES; AND 3) TO USE DATA FROM AIMS 1 AND 2 ALONGSIDE NATIONAL DATA TO CONDUCT A COST-EFFECTIVENESS ANALYSIS OF INTEGRATING COD SERVICES INTO OAT CLINICS, WITH OR WITHOUT P4P, COMPARED TO SOC OAT SITES. THIS PROPOSAL BRINGS TOGETHER EXPERTS IN THE UKRAINIAN CONTENT WITH A LONGSTANDING COLLABORATIVE RESEARCH EXPERIENCE WITH IMPLEMENTATION SCIENCE, HEALTHCARE INTEGRATION, MSBIRT, P4P, PROJECT ECHO, CLINICAL ADDICTION AND PSYCHIATRY, CLINICAL TRIALS AND COST-EFFECTIVENESS.